Chronic Inflammation in Benign Prostate Tissue Is Asso Cancer in the Placebo Arm of the Prostate Cancer Preve

Cancer Epidemiology Biomarkers and Prevention

23, 847-856

DOI: 10.1158/1055-9965.epi-13-1126

Citation Report

#	Article	IF	Citations
1	Prostatic Disease Associated withTrichomonas vaginalis. The Korean Journal of Urogenital Tract Infection and Inflammation, 2014, 9, 61.	0.1	0
2	AGE Metabolites: A Biomarker Linked to Cancer Disparity?. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2186-2191.	1.1	41
3	Intriguing data on inflammation and prostate cancer. Nature Reviews Urology, 2014, 11, 369-370.	1.9	24
4	MSMB variation and prostate cancer risk: Clues towards a possible fungal etiology. Prostate, 2014, 74, 569-578.	1.2	36
5	Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. Yearbook of Urology, 2014, 2014, 167-168.	0.1	0
6	Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2015, 75, 1160-1166.	1.2	29
7	Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. Prostate, 2015, 75, 1492-1498.	1.2	20
8	Polyomavirus BK and prostate cancer: a complex interaction of potential clinical relevance. Reviews in Medical Virology, 2015, 25, 366-378.	3.9	21
9	Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate, 2015, 75, 1167-1176.	1.2	38
10	Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2015, 75, 1403-1418.	1.2	25
11	Immune Infiltration and Prostate Cancer. Frontiers in Oncology, 2015, 5, 128.	1.3	161
12	Gold nanoparticles allow detection of early-stage edema in mice via computed tomography imaging. International Journal of Nanomedicine, 2015, 10, 3803.	3.3	15
13	Microbiology: Inflammatory evidence. Nature, 2015, 528, S130-S131.	13.7	5
14	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. International Journal of Cancer, 2015, 137, 949-958.	2.3	17
15	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. British Journal of Cancer, 2015, 112, 755-764.	2.9	62
16	Chronic inflammatory mediators enhance prostate cancer development and progression. Biochemical Pharmacology, 2015, 94, 53-62.	2.0	46
17	Inflammation and prostate cancer: friends or foe?. Inflammation Research, 2015, 64, 275-286.	1.6	48
18	Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2015, 8, 590-596.	0.7	11

#	Article	IF	Citations
19	Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?. International Urology and Nephrology, 2015, 47, 1251-1257.	0.6	10
20	Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncology, 2015, 1, 342.	3.4	70
21	A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 242-248.	2.0	49
22	Lessons Learned About Prostatic Transformation from the Age-Related Methylation of 5Î±-Reductase Type 2 Gene. American Journal of Pathology, 2015, 185, 614-616.	1.9	3
23	Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4â€‰ngâ€‰mlâ^'1, normal DRE and negative for prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 264-269.	2.0	28
24	Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prevention Research, 2015, 8, 1036-1044.	0.7	68
25	Inflammation and Infection in the Etiology of Prostate Cancer. , 2016, , 13-20.		5
26	From Inflammation to Prostate Cancer: The Role of Inflammasomes. Advances in Urology, 2016, 2016, 1-5.	0.6	50
27	Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Frontiers in Immunology, 2016, 7, 53.	2.2	33
28	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate, 2016, 76, 565-574.	1.2	5
29	Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial. Prostate, 2016, 76, 1399-1408.	1.2	6
30	Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports, 2016, 17, 2596-2606.	2.9	94
31	Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. Journal of Inflammation, 2016, 13, 35.	1.5	52
32	Inflammation and focal atrophy in prostate needle biopsy cores and association to prostatic adenocarcinoma. Annals of Diagnostic Pathology, 2016, 24, 55-61.	0.6	14
33	Association between allergic conditions and risk of prostate cancer: A Prisma-Compliant Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 35682.	1.6	9
34	Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression. Oncogene, 2016, 35, 1153-1162.	2.6	43
35	Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 463-469.	1.1	21
36	Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. Prostate Cancer and Prostatic Diseases, 2016, 19, 145-150.	2.0	20

#	Article	IF	Citations
37	Regulation of prostate cancer progression by the tumor microenvironment. Cancer Letters, 2016, 380, 340-348.	3.2	166
38	The molecular and cellular origin of human prostate cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1238-1260.	1.9	92
39	Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. Pancreatology, 2016, 16, 121-126.	0.5	19
40	Gene expression panel predicts metastaticâ€lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular Oncology, 2017, 11, 140-150.	2.1	24
41	Dying for love: Perimenopausal degeneration of vaginal microbiome drives the chronic inflammation-malignant transformation of benign prostatic hyperplasia to prostatic adenocarcinoma. Medical Hypotheses, 2017, 101, 44-47.	0.8	4
42	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 711-715.	1.4	12
43	Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer. Molecular and Cellular Oncology, 2017, 4, e1279723.	0.3	13
44	Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase. Molecular Cancer Research, 2017, 15, 1138-1152.	1.5	66
45	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research, 2017, 10, 319-326.	0.7	23
46	The role of prostatic inflammation in the development and progression of benign and malignant diseases. Current Opinion in Urology, 2017, 27, 99-106.	0.9	54
47	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. Journal of Leukocyte Biology, 2017, 102, 393-406.	1.5	55
48	Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 845-853.	1.1	52
49	Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate, 2017, 77, 908-919.	1.2	21
50	Nonsteroidal antiâ€inflammatory drugs (<scp>NSAID</scp>s) and prostate cancer risk: results from the <scp>EPICAP</scp> study. Cancer Medicine, 2017, 6, 2461-2470.	1.3	48
51	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1549-1557.	1.1	61
52	A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Scientific Reports, 2017, 7, 15624.	1.6	27
53	Telomeres and telomerase in prostate cancer development and therapy. Nature Reviews Urology, 2017, 14, 607-619.	1.9	85
54	â€œTextural analysis of multiparametric MRI detects transition zone prostate cancerâ€• European Radiology, 2017, 27, 2348-2358.	2.3	74

#	Article	IF	Citations
55	Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. Prostate, 2017, 77, 412-424.	1.2	43
56	Natriuretic Peptides: The Case of Prostate Cancer. Molecules, 2017, 22, 1680.	1.7	9
57	Prevalence of Flp Pili-Encoding Plasmids in Cutibacterium acnes Isolates Obtained from Prostatic Tissue. Frontiers in Microbiology, 2017, 8, 2241.	1.5	21
58	Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 1542.	1.8	25
59	Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set. Urologia Internationalis, 2018, 100, 456-462.	0.6	14
60	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	1.1	1
61	Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology, 2018, 15, 235-250.	1.9	46
62	Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis. Journal of Urology, 2018, 199, 1174-1181.	0.2	31
63	Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer and Prostatic Diseases, 2018, 21, 147-152.	2.0	26
64	Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. International Journal of Cancer, 2018, 142, 2254-2262.	2.3	40
65	Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030494.	2.9	4
66	Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes and Control, 2018, 29, 455-464.	0.8	6
67	Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer. Oncology Letters, 2018, 15, 5236-5242.	0.8	12
68	Immune profiling of human prostate epithelial cells determined by expression of p38/TRAFâ€6/ERK MAP kinases pathways. Kaohsiung Journal of Medical Sciences, 2018, 34, 125-133.	0.8	5
69	Prostate cancer immunotherapy. Current Opinion in Urology, 2018, 28, 15-24.	0.9	40
70	The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews Urology, 2018, 15, 11-24.	1.9	311
71	Analysis of Tumor Biology to Advance Cancer Health Disparity Research. American Journal of Pathology, 2018, 188, 304-316.	1.9	24
72	Serum and tissue monocyte differentiation in PSA value 4â€“10â€‰ng/mL prostate cancer and benign prostatic hyperplasia. European Journal of Inflammation, 2018, 16, 205873921881266.	0.2	1

#	Article	IF	Citations
73	Association between large prostate calculi and prostate cancer. Archivio Italiano Di Urologia Andrologia, 2018, 90, 181-183.	0.4	1
74	RON Receptor Tyrosine Kinase in Pancreatic Cancer Progression. , 2018, , 71-81.		0
75	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine, 2018, 7, 156.	1.0	10
76	The distribution of BCG prostatitis: A clue for pathogenetic processes?. Prostate, 2018, 78, 1134-1139.	1.2	11
77	Polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the Black Sea Region in Turkey. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 704-708.	0.7	4
78	Inflammation and Prostate Cancer. Advances in Experimental Medicine and Biology, 2018, 1095, 41-65.	0.8	28
79	Prostate cancer multifocality, the index lesion, and the microenvironment. Current Opinion in Urology, 2018, 28, 499-505.	0.9	27
80	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. Prostate, 2018, 78, 1172-1180.	1.2	17
81	Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration. Clinical Cancer Research, 2018, 24, 5622-5634.	3.2	77
83	Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy. BJU International, 2019, 123, 91-97.	1.3	11
84	Omegaâ€3 fatty acids decrease prostate cancer progression associated with an antiâ€tumor immune response in eugonadal and castrated mice. Prostate, 2019, 79, 9-20.	1.2	28
85	Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10â€‰ng/ml: results of 564 consecutive cases. Therapeutic Advances in Urology, 2019, 11, 175628721986860.	0.9	5
86	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Scientific Reports, 2019, 9, 10662.	1.6	32
87	Differential expression of the TPÎ± and TPÎ² isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPÎ² during monocyte-macrophage differentiation. Experimental and Molecular Pathology, 2019, 110, 104277.	0.9	4
88	Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men. Korean Journal of Parasitology, 2019, 57, 21-25.	0.5	14
89	Age-Specific Serum Total and Free Estradiol Concentrations in Healthy Men in US Nationally Representative Samples. Journal of the Endocrine Society, 2019, 3, 1825-1836.	0.1	7
90	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nuclear Medicine and Biology, 2019, 68-69, 66-79.	0.3	19
91	Circulating inflammation markers and prostate cancer. Prostate, 2019, 79, 1338-1346.	1.2	15

#	Article	IF	Citations
92	Epidemiology of Prostate Cancer. World Journal of Oncology, 2019, 10, 63-89.	0.6	1,503
93	Lycopene exerts anti-inflammatory effect to inhibit prostate cancer progression. Asian Journal of Andrology, 2019, 21, 80.	0.8	33
94	Dietary inflammatory index (DII) and risk of prostate cancer in a caseâ€“control study among Black and White US Veteran men. Prostate Cancer and Prostatic Diseases, 2019, 22, 580-587.	2.0	14
95	Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types. Scientific Reports, 2019, 9, 1603.	1.6	49
96	Metabolic Health: Inflammation and Men's Health. , 2019, , 101-119.		0
97	Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 464.	3.5	42
98	A Systematic Review and Meta-analysis of Associations between Clinical Prostatitis and Prostate Cancer: New Estimates Accounting for Detection Bias. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1594-1603.	1.1	14
99	Evaluation of urinary and serum level of chemokine (Câ€€ motif) ligand 2 as a potential biomarker in canine urothelial tumours. Veterinary and Comparative Oncology, 2019, 17, 11-20.	0.8	7
100	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 2019, 206, 91-106.	2.2	20
101	Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Medicine, 2019, 8, 1110-1123.	1.3	69
102	Nonneoplastic Diseases of the Prostate. , 2020, , 358-414.e13.		0
103	Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans. Anticancer Research, 2020, 40, 27-34.	0.5	9
104	Phenotypic switching and prostate diseases: a model proposing a causal link between benign prostatic hyperplasia and prostate cancer. , 2020, , 569-589.		0
105	Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5484.	1.8	36
106	The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer. Cells, 2020, 9, 2342.	1.8	34
107	Application of Anti-Inflammatory Agents in Prostate Cancer. Journal of Clinical Medicine, 2020, 9, 2680.	1.0	12
108	Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors. Arab Journal of Urology Arab Association of Urology, 2020, 18, 148-154.	0.7	3
109	Prostate carcinogenesis: inflammatory storms. Nature Reviews Cancer, 2020, 20, 455-469.	12.8	114

#	Article	IF	Citations
110	Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer. Scientific Reports, 2020, 10, 9093.	1.6	9
111	Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?. Canadian Urological Association Journal, 2020, 14, E568-E573.	0.3	4
112	Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options. Journal of Immunology Research, 2020, 2020, 1-7.	0.9	9
113	The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2020, 80, 895-905.	1.2	0
114	IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalisÂpromotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages. PLoS Neglected Tropical Diseases, 2020, 14, e0008126.	1.3	52
115	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2020, 13, 853-862.	0.7	8
116	Chronic Periodontal Disease increases risk for Prostate Cancer in Elderly individuals in South Korea: a Retrospective Nationwide Population-based Cohort Study. Journal of Cancer, 2020, 11, 4716-4723.	1.2	8
117	Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Research, 2020, 80, 1615-1623.	0.4	120
118	Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly lowâ€grade cancer. Prostate, 2020, 80, 687-697.	1.2	3
119	High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 668-675.	1.1	16
120	Human microbiome and prostate cancer development: current insights into the prevention and treatment. Frontiers of Medicine, 2021, 15, 11-32.	1.5	17
121	Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutrition and Cancer, 2021, , 1-8.	0.9	2
122	Inflammation Endows Benign Prostatic Hyperplasia Cells With Similar Physical Properties to Prostate Cancer Cells. IEEE Open Journal of Nanotechnology, 2021, 2, 52-58.	0.9	0
123	The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: a narrative review. Journal of Clinical and Translational Research, 0, , .	0.3	9
124	Why Do Epidemiologic Studies Find an Inverse Association Between Intraprostatic Inflammation and Prostate Cancer: A Possible Role for Colliding Bias?. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 255-259.	1.1	4
125	Dietary Factors and Prostate Cancer Development, Progression, and Reduction. Nutrients, 2021, 13, 496.	1.7	47
126	Growth and differentiation factor 15 and NFâ€ºB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection. Cancer Medicine, 2021, 10, 3013-3025.	1.3	10
127	Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development. Frontiers in Genetics, 2021, 12, 652747.	1.1	42

#	Article	IF	Citations
128	Sleep disorders and prostate cancer prognosis. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	0.6	3
129	Immune Inflammation Pathways as Therapeutic Targets to Reduce Lethal Prostate Cancer in African American Men. Cancers, 2021, 13, 2874.	1.7	9
130	Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?. Uro, 2021, 1, 54-59.	0.3	4
131	Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men. Journal of the National Cancer Institute, 2022, 114, 123-129.	3.0	12
132	Urinary PGE-M in Men with Prostate Cancer. Cancers, 2021, 13, 4073.	1.7	3
133	Crosstalk between Autophagy and Inflammatory Processes in Cancer. Life, 2021, 11, 903.	1.1	11
134	Aging of the progenitor cells that initiate prostate cancer. Cancer Letters, 2021, 515, 28-35.	3.2	13
135	The presence of chronic inflammation in positive prostate biopsy is associated with upgrading in radical prostatectomy. Archivio Italiano Di Urologia Andrologia, 2021, 93, 280-284.	0.4	5
136	Prostate cancer: Therapeutic prospect with herbal medicine. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100034.	1.7	13
137	Dietary Carcinogens and DNA Adducts in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 29-55.	0.8	10
138	Association of High miR-182 Levels with Low-Risk Prostate Cancer. American Journal of Pathology, 2019, 189, 911-923.	1.9	14
140	Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence. PLoS ONE, 2020, 15, e0242970.	1.1	8
141	Prevention of Prostate Cancer: Outcomes of Clinical Trials and Future Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e76-e80.	1.8	9
142	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	0.8	10
143	ERÎ² regulation of NF-Î¹B activation in prostate cancer is mediated by HIF-1. Oncotarget, 2015, 6, 40247-40254.	0.8	52
144	The Possibility of Preventive and Therapeutic Use of Green Tea Catechins in Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1223-1231.	0.9	14
145	The Role of Chronic Inflammation in Prostate Carcinogenesis: A Follow-Up Study. Annals of Urologic Oncology, 2019, , 1-8.	0.0	3
146	Inflammation in prostate cancer progression and therapeutic targeting. Translational Andrology and Urology, 2015, 4, 455-63.	0.6	55

#	Article	IF	Citations
147	Eosinophilic metaplasia in transurethral resection of the prostate. Indian Journal of Pathology and Microbiology, 2020, 63, 423.	0.1	2
148	A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet. PeerJ, 2015, 3, e1080.	0.9	22
149	Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies. Frontiers in Pharmacology, 2021, 12, 732266.	1.6	17
152	A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia. Jundishapur Journal of Chronic Disease Care, 2016, 6, .	0.1	2
153	Prostatakarzinom: Epidemiologie und Risikofaktoren. Springer Reference Medizin, 2020, , 1-21.	0.0	0
155	Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies. Frontiers in Cell and Developmental Biology, 2021, 9, 745177.	1.8	21
156	REPLY BY THE AUTHORS: Comment on Polygamy, Sexual Behavior in a Population Under Risk for Prostate Cancer Diagnostic: An Observational Study From the Black Sea Region in Turkey. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 877-878.	0.7	0
157	Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. Current Drug Therapy, 2020, 15, 168-180.	0.2	0
158	Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases. , 2015, 2, .		16
159	The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. American Journal of Clinical and Experimental Urology, 2018, 6, 123-132.	0.4	1
160	Clinical significance of urine prostatic exosomal protein in the diagnosis of prostate cancer. American Journal of Cancer Research, 2019, 9, 1074-1078.	1.4	5
161	Mass cytometry reveals species-specific differences and a new level of complexity for immune cells in the prostate. American Journal of Clinical and Experimental Urology, 2019, 7, 281-296.	0.4	3
162	The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review. Journal of Clinical and Translational Research, 2021, 7, 333-376.	0.3	6
163	Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene, 2022, , .	2.6	6
164	The onset of age-related benign prostatic hyperplasia is concomitant with increased serum and prostatic expression of VEGF in rats: Potential role of VEGF as a marker for early prostatic alterations. Theriogenology, 2022, 183, 69-78.	0.9	1
165	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper. Cancers, 2022, 14, 675.	1.7	10
166	Health inequity drives disease biology to create disparities in prostate cancer outcomes. Journal of Clinical Investigation, 2022, 132, .	3.9	17
167	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. Cancers, 2022, 14, 1367.	1.7	10

#	Article	IF	Citations
168	Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. Journal of Endocrinological Investigation, 2022, 45, 1413-1425.	1.8	4
169	Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-Î”G carriers. Prostate Cancer and Prostatic Diseases, 2023, 26, 338-346.	2.0	3
170	Template-Independent Poly(A)-Tail Decay and RNASEL as Potential Cellular Biomarkers for Prostate Cancer Development. Cancers, 2022, 14, 2239.	1.7	5
171	Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. Frontiers in Immunology, 2022, 13, .	2.2	14
172	The vaginal microbiome: A complex milieu affecting risk of human papillomavirus persistence and cervical cancer. Current Problems in Cancer, 2022, 46, 100877.	1.0	7
173	Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis. Biomedicines, 2022, 10, 1672.	1.4	5
174	A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2022, 21, 1337-1347.	1.9	7
175	The association between <scp>PI3K</scp> , <scp>JAK</scp> / <scp>STAT</scp> pathways with the <scp>PDL</scp> â€1 expression in prostate cancer. Andrologia, 0, , .	1.0	0
176	Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment. Cancers, 2022, 14, 4412.	1.7	4
177	Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumorâ€™s Immune Environment. Cancers, 2022, 14, 4293.	1.7	12
178	Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 2022, 27, 5730.	1.7	133
179	The association between prostatitis and risk of prostate cancer: a National Health Insurance Database study. World Journal of Urology, 2022, 40, 2781-2787.	1.2	5
180	The regulatory role of PDE4B in the progression of inflammatory function study. Frontiers in Pharmacology, 0, 13, .	1.6	5
181	Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study. Research and Reports in Urology, 0, Volume 14, 369-377.	0.6	0
182	Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. BMC Cancer, 2023, 23, .	1.1	8
183	Tumor-associated macrophages in prostate cancer: role in progression and therapy. , 2023, , 153-180.		0
187	The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nature Reviews Urology, 2023, 20, 706-718.	1.9	4
192	Role of phospholipase A2 in squamous cell carcinoma and breast cancer. , 2023, , 315-335.		0

#	Article	IF	Citations
195	Cancer stem cells, signalling pathways and chemopreventive effects of phytochemicals in androgen-regulated cancers. , 2024, , 409-437.		0